Mutant prevention and minimum inhibitory concentration drug values for enrofloxacin, ceftiofur, florfenicol, tilmicosin and tulathromycin tested against swine pathogens Actinobacillus pleuropneumoniae, Pasteurella multocida and Streptococcus suis

Autor: Shantelle D. Fitch, Joseph M Blondeau
Jazyk: angličtina
Rok vydání: 2019
Předmět:
0301 basic medicine
Florfenicol
Streptococcus suis
Swine
animal diseases
Pathology and Laboratory Medicine
Disaccharides
chemistry.chemical_compound
Heterocyclic Compounds
Zoonoses
Drug Resistance
Multiple
Bacterial

Medicine and Health Sciences
Tulathromycin
Tilmicosin
Animal Husbandry
Pasteurella multocida
Mammals
Swine Diseases
Enrofloxacin
Multidisciplinary
biology
Antimicrobials
Actinobacillus pleuropneumoniae
Eukaryota
Drugs
Pneumococcus
Bacterial Pathogens
Anti-Bacterial Agents
Infectious Diseases
Medical Microbiology
Vertebrates
Medicine
Pathogens
Ceftiofur
Research Article
medicine.drug
Veterinary Medicine
Science
030106 microbiology
Microbial Sensitivity Tests
Microbiology
03 medical and health sciences
Microbial Control
medicine
Animals
Microbial Pathogens
Pharmacology
Thiamphenicol
Bacteria
Organisms
Biology and Life Sciences
Streptococcus
biology.organism_classification
Cephalosporins
030104 developmental biology
chemistry
Amniotes
Veterinary Science
Tylosin
Antimicrobial Resistance
Zdroj: PLoS ONE, Vol 14, Iss 1, p e0210154 (2019)
PLoS ONE
ISSN: 1932-6203
Popis: Actinobacillus pleuropneumoniae, Pasteurella multocida and Streptococcus suis are prevalent bacterial causes of swine infections. Morbidity, mortality and positively impacting the financial burden of infection occurs with appropriate antimicrobial therapy. Increasing antimicrobial resistance complicates drug therapy and resistance prevention is now a necessity to optimize therapy and prolong drug life. Mutant bacterial cells are said to arise spontaneously in bacterial densities of 107−109 or greater colony forming units/ml. Antibiotic drug concentration inhibiting growth of the least susceptible cell in these high density populations has been termed the mutant prevention concentration (MPC). In this study MPC and minimum inhibitory concentration (MIC) values of ceftiofur, enrofloxacin, florfenicol, tilmicosin and tulathromycin were determined against the swine pathogens A. pleuropneumoniae, P.multocida and S. suis. The following MIC90/MPC90 values (mg/L) for 67 A. pleuropneumoniae and 73 P. multocida strains respectively were as follows: A. pleuropneumoniae 0.031/0.5, ≤0.016/0.5, 0.5/2, 4/32, 2/32; P. multocida 0.004/0.25, 0.016/0.125, 0.5/0.5, 8/16, 0.5/1. For 33 S. suis strains, MIC90 values (mg/L) respectively were as follows: 1, 0.25, 4, ≥8 and ≥8. A total of 16 S. suis strains with MIC values of 0.063–0.5 mg/L to ceftiofur and 0.25–0.5 mg/L to enrofloxacin were tested by MPC; MPC values respectively were 0.5 and 1 mg/L respectively. MPC concentrations provide a dosing target which may serve to reduce amplification of bacterial subpopulations with reduced antimicrobial susceptibility. Drug potency based on MIC90 values was ceftiofur > enrofloxacin >florfenicol = tulathromycin > tilmicosin; based on MPC90 values was enrofloxacin > ceftiofur > tulathromycin > florfenicol ≥ tilmicosin.
Databáze: OpenAIRE